The results show that patients with high juxta-tumoral αSMA expression (0–10 μm) had shorter progression-free survival (p = 0.0067) and overall survival (p = 0.0056) compared to patients with low juxta-tumoral αSMA expression (Fig. 1i, k), while αSMA expression levels in the regions of 10–20 μm distant to tumor cells were not correlated with patient outcome (Figs. 1j, l). The gene discussed is ACTA1; the disease is neoplasm.